Compare CCNE & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCNE | FULC |
|---|---|---|
| Founded | 1865 | 2015 |
| Country | United States | United States |
| Employees | 950 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 818.2M | 718.4M |
| IPO Year | N/A | 2019 |
| Metric | CCNE | FULC |
|---|---|---|
| Price | $27.27 | $6.89 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $32.00 | $16.38 |
| AVG Volume (30 Days) | 118.2K | ★ 1.2M |
| Earning Date | 04-13-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.61% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.21 | N/A |
| Revenue Next Year | $7.00 | N/A |
| P/E Ratio | $11.84 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.32 | $2.32 |
| 52 Week High | $30.84 | $15.74 |
| Indicator | CCNE | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 43.76 | 29.67 |
| Support Level | $26.25 | $6.33 |
| Resistance Level | $28.32 | $7.28 |
| Average True Range (ATR) | 0.82 | 0.47 |
| MACD | -0.07 | -0.06 |
| Stochastic Oscillator | 42.44 | 10.38 |
CNB Financial Corp is a Pennsylvania-chartered bank. The bank is a full-service bank engaging in a full range of banking activities and services for individual, business, governmental and institutional customers. These activities and services principally include checking, savings, and time deposit accounts; real estate, commercial, industrial, residential and consumer loans; and a variety of other specialized financial services. Its Private Client Solutions division offers a full range of client services, including private banking and wealth and asset management. The banking segment derives its revenue through the operations as a full-service bank services, including trust and wealth management services, for individual, business, governmental, and institutional customers.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.